This post features the work McLeod et al. recently published in Nature Communications, highlighting a creative approach to anti-malaria vaccine development. Specifically, the researchers identify the most potent antibody to date against the Plasmodium surface protein Pfs25 and use molecular characterization to provide valuable insights into the vaccine-antibody interaction.
In the lab of Dr. John Brumell at SickKids, Dr. D’Costa and colleagues performed the first systematic investigation of bacterial effector-host protein interactions using BioID. They discovered novel targets of a Salmonella effector SifA, providing molecular insights into how this bacterial protein manipulates host cells to promote intracellular survival.